title: Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers.
abstract: Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade. New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs. Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival, although the effect was minimal. Little or no improvement in survival with recent molecular-targeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer. Recently, the non-gemcitabine-based-regimen of FOLFIRINOX showed significantly greater overall survival compared with gemcitabine for the first time. For biliary tract cancer, gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy. Further improvement in survival is expected by the addition of cetuximab.
authors: Minoru Tada, Yousuke Nakai, Takashi Sasaki, Tsuyoshi Hamada, Rie Nagano, Dai Mohri, Koji Miyabayashi, Keisuke Yamamoto, Hirofumi Kogure, Kazumichi Kawakubo, Yukiko Ito, Natsuyo Yamamoto, Naoki Sasahira, Kenji Hirano, Hideaki Ijichi, Keishuke Tateishi, Hiroyuki Isayama, Kazuhiko Koike, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
authors: Minoru
authors: M
authors: Tada
authors: Yousuke
authors: Y
authors: Nakai
authors: Takashi
authors: T
authors: Sasaki
authors: Tsuyoshi
authors: T
authors: Hamada
authors: Rie
authors: R
authors: Nagano
authors: Dai
authors: D
authors: Mohri
authors: Koji
authors: K
authors: Miyabayashi
authors: Keisuke
authors: K
authors: Yamamoto
authors: Hirofumi
authors: H
authors: Kogure
authors: Kazumichi
authors: K
authors: Kawakubo
authors: Yukiko
authors: Y
authors: Ito
authors: Natsuyo
authors: N
authors: Yamamoto
authors: Naoki
authors: N
authors: Sasahira
authors: Kenji
authors: K
authors: Hirano
authors: Hideaki
authors: H
authors: Ijichi
authors: Keishuke
authors: K
authors: Tateishi
authors: Hiroyuki
authors: H
authors: Isayama
authors: Masao
authors: M
authors: Omata
authors: Kazuhiko
authors: K
authors: Koike
references: Gastroenterology. 2005 May;128(6):1642-54
references: 15887156
references: Lancet Oncol. 2010 Dec;11(12):1142-8
references: 21071270
references: Cancer Chemother Pharmacol. 2008 Apr;61(4):615-21
references: 17520253
references: Oncology. 2009;77(1):71-4
references: 19556812
references: Oncology. 2005;68(2-3):171-8
references: 16006754
references: J Clin Oncol. 2007 May 20;25(15):1960-6
references: 17452677
references: Oncology. 2009;77(5):300-3
references: 19923869
references: J Clin Oncol. 2007 Jun 1;25(16):2212-7
references: 17538165
references: Pancreas. 2010 Oct;39(7):989-93
references: 20467352
references: N Engl J Med. 2009 Apr 2;360(14):1408-17
references: 19339720
references: J Clin Oncol. 2005 May 20;23(15):3509-16
references: 15908661
references: J Clin Oncol. 1997 Jun;15(6):2403-13
references: 9196156
references: Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55
references: 18214482
references: J Clin Oncol. 2010 Aug 1;28(22):3617-22
references: 20606091
references: Gut. 2005 Mar;54(3):385-7
references: 15710987
references: J Clin Oncol. 2010 Aug 1;28(22):3605-10
references: 20606093
references: Cancer Chemother Pharmacol. 2010 May;65(6):1101-7
references: 19707761
references: Br J Cancer. 2010 Aug 10;103(4):469-74
references: 20628385
references: Clin Gastroenterol Hepatol. 2006 Oct;4(10):1265-70
references: 16979953
references: Gastroenterology. 1991 Jan;100(1):233-8
references: 1983826
references: Invest New Drugs. 2011 Dec;29(6):1488-93
references: 20607585
references: Br J Cancer. 2006 Jun 5;94(11):1575-9
references: 16721372
references: J Clin Oncol. 2009 Nov 20;27(33):5513-8
references: 19858379
references: J Clin Oncol. 2010 Jan 1;28(1):69-76
references: 19933912
references: Chemotherapy. 2008;54(4):302-8
references: 18689983
references: Br J Cancer. 2010 Nov 23;103(11):1644-8
references: 20978506
references: Br J Cancer. 2004 Nov 15;91(10):1769-74
references: 15505626
references: Cancer Chemother Pharmacol. 2006 May;57(5):647-53
references: 16142487
references: Cancer. 1992 Mar 1;69(5):1115-8
references: 1739910
references: N Engl J Med. 2010 Apr 8;362(14):1273-81
references: 20375404
references: Cancer. 1990 Sep 1;66(5):930-5
references: 2167148
references: J Clin Oncol. 2010 Apr 1;28(10):1645-51
references: 20194854